DiaCarta's Positive Clinical Trial Results Unveiled
DiaCarta Inc., a pioneering molecular diagnostic firm, has recently shared encouraging clinical trial findings regarding its innovative blood-based test designed for triaging patients who test positive for the fecal immunochemical test (FIT) in colorectal cancer (CRC) screening. This groundbreaking study data, released through the Journal of Molecular Pathology, highlights how the QuantiDNA™ test can effectively minimize the necessity for colonoscopy procedures by 33%, demonstrating that it is on par with standard methods for identifying significant colorectal lesions.
Details of the Clinical Trial Study
The clinical trial, focused on the Triage of FIT Positive Patients enrolled in CRC screening initiatives, took place between 2019 and 2022. A total of 711 participants of various backgrounds, aged between 50 and 74 years, took part in a comprehensive study organized by a public healthcare entity. Individuals who exhibited a FIT+ result and agreed to study participation were subjected to both the blood test and a follow-up colonoscopy. This approach ensured a thorough comparison between traditional practices and the new blood-based technique. The trial received ethical approval in late 2018 and statistical analyses were rigorously conducted to validate the outcomes.
The Clinical Significance
Dr. Mauro Scimia, Medical Director and Senior Business Director of DiaCarta, emphasized the potential of this study in reforming CR screening protocols. He mentioned that in Europe, a majority of patients who are initially diagnosed as FIT positive ultimately do not have significant findings upon colonoscopy, which leads to unnecessary procedures and anxiety for patients. By implementing the QuantiDNA™ test, healthcare providers can improve patient experiences while managing resources more effectively.
The Company and Its Vision
Dr. Adam (Aiguo) Zhang, DiaCarta’s President and CEO, also expressed his satisfaction with the trial results. He noted that the strong performance of the blood-based test not only meets the company’s mission of enhancing cancer testing via liquid biopsy but also marks a vital step toward integrating the test into everyday clinical practice.
About DiaCarta
Founded with a commitment to transformation in patient care, DiaCarta is at the forefront of molecular diagnostics. Their revolutionary XNA technology grants high sensitivity in detecting biomarkers crucial for early cancer detection. Particularly, their early detection test for colorectal cancer reflects their efforts towards successful healthcare innovations.
Additionally, DiaCarta has introduced the isobDNA™ technology, further enhancing detection levels while eradicating the need for complex RNA/DNA extraction processes. The RadTox™ pan-cancer blood test is another product that personalizes cancer treatments, providing real-time insights into tumor responses and treatment efficacy.
Company's Operations and Commitment to Quality
Based in Pleasanton, California, DiaCarta operates an ISO-certified and GMP-compliant facility, offering CLIA-certified laboratory services. Their tests are not only effective but also accessible, as they are covered by most medical insurances.
Contacting DiaCarta
All inquiries regarding DiaCarta's services or studies can be directed through the following:
Phone Number: 1-800-246-8878
Email: [email protected]
Frequently Asked Questions
What is the purpose of DiaCarta's blood test?
The blood test is designed to triage patients who test positive for colorectal cancer screening, reducing unnecessary colonoscopies.
What were the findings of the clinical trial?
The trial showed a 33% reduction in the need for colonoscopy while maintaining efficacy in detecting significant lesions.
Who conducted the clinical trial?
The trial involved collaboration with a public healthcare organization and was approved by the appropriate ethical committees.
What technologies does DiaCarta utilize?
DiaCarta employs innovative technologies like XNA and isobDNA™ for developing sensitive diagnostic tests for early cancer detection.
How can I contact DiaCarta for more information?
You can reach DiaCarta by phone at 1-800-246-8878 or through their official email for inquiries.
